Spectrawave
SpectraWAVE, acquired by Philips in January 2026, develops the HyperVue Imaging System combining DeepOCT and NIRS intravascular imaging with the X1-FFR wire-free physiology software, sold to U.S. hospitals and cardiac catheterization labs for image-guided percutaneous coronary interventions.
- Company typePrivate
- Founded2017
- HeadquartersWaltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spectrawave does
SpectraWAVE is a U.S. medical device company that develops AI-enabled intravascular imaging and physiological assessment systems for interventional cardiology. Founded in 2017 and headquartered in Bedford, Massachusetts, the company was acquired by Royal Philips in January 2026 and now operates within Philips' Image-Guided Therapy business. Its flagship product, the HyperVue Imaging System, combines proprietary DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) on a single console, paired with the single-use Starlight Imaging Catheter (2.5 Fr, indicated for vessels 2.0–5.2 mm). The platform performs a 100 mm pullback in under one second at 120 mm/s, supports low- or no-contrast acquisition, and applies AI-powered automated image review at the bedside for lipid, calcium, EEL, lumen, and stent metrics. The X1-FFR software add-on (FDA-cleared October 2025) derives fractional flow reserve from a single angiogram without pressure wires or adenosine drugs, available exclusively on HyperVue.
The company's revenue model is a hybrid of capital equipment sales (HyperVue consoles) and recurring single-use catheter consumables (Starlight), sold through a direct enterprise field sales force targeting U.S. hospitals and cardiac catheterization labs performing percutaneous coronary interventions. Go-to-market is led by a dedicated commercial organization including a Chief Commercial Officer, VP of Sales, and VP of Strategic Accounts. Customer segments are narrowly defined as interventional cardiology departments and cath labs; the company does not publicly disclose pricing, contract structures, or named hospital customers. Strategic and financial backers historically included Johnson & Johnson Innovation (JJDC, Series B lead), Deerfield Management, S3 Ventures, Lumira Ventures, SV Health Investors, and Orchestra BioMed. Co-founders include prominent interventional cardiologists Gregg Stone (Mount Sinai), Guillermo Tearney (MGH), James Muller (Brigham & Women's), and Jeffrey O'Donnell (Runway Healthcare), lending clinical credibility and KOL access.
Spectrawave firmographics
Firmographics- Name
- Spectrawave
- Legal name
- SpectraWAVE, Inc.
- Website
- https://spectrawave.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- SpectraWAVE, acquired by Philips in January 2026, develops the HyperVue Imaging System combining DeepOCT and NIRS intravascular imaging with the X1-FFR wire-free physiology software, sold to U.S. hospitals and cardiac catheterization labs for image-guided percutaneous coronary interventions.
- Ownership category
- akta.pro rank
Spectrawave industry classification
Industry- Product category
- Intravascular Imaging Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industry
- Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI)
Keywords
Where Spectrawave is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spectrawave business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Hardware Sales: Sale of HyperVue Imaging Systems to hospitals and cardiac catheterization labs. The system includes console hardware and specialized imaging catheters (Starlight Imaging Catheter) that are used in coronary procedures.
- Consumables and Imaging Catheters: Recurring revenue from single-use imaging catheters and consumables required for each procedure. The Starlight Imaging Catheter is intended for use in coronary interventions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical imaging system - pricing not publicly disclosed |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Spectrawave product offering
Product offeringCore offering
SpectraWAVE develops and sells the HyperVue Imaging System, an intravascular medical device that combines DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) to deliver comprehensive coronary artery imaging and plaque characterization during percutaneous coronary interventions. The platform is paired with the Starlight Imaging Catheter and the X1-FFR software module, which derives fractional flow reserve (FFR) from a single angiogram without wires or drugs, using AI-powered automated analysis at the bedside.
Product overview
SpectraWAVE offers a unified medical device platform combining the HyperVue Imaging System as the core product with integrated X1-FFR software module. The HyperVue provides comprehensive DeepOCT+NIRS intravascular imaging for coronary artery visualization, while X1-FFR delivers angiography-derived fractional flow reserve physiology assessment. Both products are available on a single platform, enabling clinicians to perform both imaging and physiology assessments during percutaneous coronary interventions. The system features AI-powered automated analysis for fast, informed PCI decision-making.
Differentiator
Problem solved
Functional benefit
Brands
- HyperVue: Intravascular imaging system combining DeepOCT and NIRS technologies for coronary artery disease treatment
- X1-FFR
- DeepOCT
- Starlight
Products and services
- HyperVue Imaging System Intravascular imaging medical device combining DeepOCT and NIRS to image coronary arteries during percutaneous coronary interventions, indicated for patients who are candidates for transluminal interventional procedures. Provides rapid 100mm pullback acquisition in less than a second, no-flush prep catheter design, and AI-powered automated analysis at the bedside with customizable structural and compositional overlays.
- X1-FFR AI-enabled, wire-free, drug-free fractional flow reserve software available exclusively on the HyperVue Imaging System. Derives FFR from a single angiogram within about one minute without pressure wires or adenosine, using AI-enabled vessel segmentation and hands-free angio co-registration.
- Starlight Imaging Catheter Single-use imaging catheter for use with the HyperVue Imaging System, intended for vessels 2.0 to 5.2 mm in diameter. Features a no-flush prep closed system with a low-profile 2.5 Fr design for rapid pullback acquisition. Not intended for use in target vessels that have undergone previous bypass procedures.
Companies that use Spectrawave
Customer profileSegments2 records
Ideal customer profiles1 record
Spectrawave technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature9 records
Spectrawave partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Royal PhilipsflagshipRoyal Philips agreed to acquire SpectraWAVE in December 2025, with the acquisition completing in January 2026. The acquisition integrates SpectraWAVE's HyperVue Imaging System and X1-FFR with Philips' existing Azurion platform and IVUS technologies to enhance Philips' image-guided therapy offerings in coronary interventions.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Spectrawave competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare provides angiography and cardiology imaging systems that interface with intracoronary imaging and physiology devices — an adjacent incumbent in the cath-lab ecosystem.
- Medtronic: Medtronic is a broad incumbent in interventional cardiology with historical FFR offerings (acquired via RDM / legacy businesses) that overlap with the clinical use cases SpectraWAVE targets.
- Royal Philips: Now SpectraWAVE's parent, Philips sells the Azurion platform and an existing IVUS line; SpectraWAVE's HyperVue and X1-FFR are being integrated into this broader image-guided therapy portfolio.
- Siemens Healthineers: Siemens Healthineers sells cardiology imaging systems and post-processing software used in coronary procedures; an adjacent incumbent whose installed base competes for cath-lab workflow integration.
Direct peers
- Abbott: Abbott markets the Ilumien Optis OCT platform and Dragonfly imaging catheter — the dominant commercial OCT competitor to SpectraWAVE's HyperVue in intracoronary imaging.
- ACIST Medical Systems (Bracco): ACIST markets the Navvus microcatheter for FFR measurement and HemoSphere physiology tools — a direct competitor to SpectraWAVE's physiology offering, now part of Bracco's imaging franchise.
- Boston Scientific: Boston Scientific's IVUS portfolio (OptiCross, iLab) competes head-to-head with HyperVue in cath-lab imaging and shares SpectraWAVE's interventional cardiology customer base.
Emerging players
- HeartFlow: HeartFlow's FFR-CT provides non-invasive coronary physiology from CT angiography, competing for the same clinical question (do we need invasive FFR?) that X1-FFR addresses from the cath lab.
- Elucid Bioimaging: Elucid develops AI-based cardiovascular imaging analysis software (e.g., vascuCAP), overlapping with SpectraWAVE's AI-powered image analysis positioning in cardiac imaging informatics.
- CathWorks: CathWorks' FFRangio computes FFR from angiograms without pressure wires — a directly competing approach to SpectraWAVE's X1-FFR, targeting the same wire-free FFR workflow.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Spectrawave social profiles
Digital presenceSpectrawave financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spectrawave leadership team
Management profileNumber of profiles
Profiles13 records
Spectrawave funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spectrawave M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spectrawave
What does Spectrawave do?
SpectraWAVE develops and sells the HyperVue Imaging System, an intravascular medical device that combines DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) to deliver comprehensive coronary artery imaging and plaque characterization during percutaneous coronary interventions. The platform is paired with the Starlight Imaging Catheter and the X1-FFR software module, which derives fractional flow reserve (FFR) from a single angiogram without wires or drugs, using AI-powered automated analysis at the bedside.
Is Spectrawave a public or private company?
Spectrawave is a private company. It is classified as corporate owned and is currently acquired.
When was Spectrawave founded?
Spectrawave was founded in 2017. It employs 51 to 100 people.
Where is Spectrawave based?
Spectrawave is headquartered in Waltham, United States, in the North America region.
How does Spectrawave make money?
Two revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are consumables and Imaging Catheters.
Who are Spectrawave's main competitors?
Broad incumbents on record are GE HealthCare, Medtronic, Royal Philips and Siemens Healthineers. Direct peers are Abbott, ACIST Medical Systems (Bracco) and Boston Scientific. Emerging players are HeartFlow, Elucid Bioimaging and CathWorks.
Does Spectrawave have an API?
No public API is recorded for Spectrawave.
What industry is Spectrawave in?
Spectrawave's product category is Intravascular Imaging Systems. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA). Its NAICS code is 334510 and its SIC code is 3841.